|Bid||75.51 x 800|
|Ask||78.52 x 1800|
|Day's Range||74.97 - 76.27|
|52 Week Range||51.62 - 99.82|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||103.71|
Ringing today's opening bells are Connie Lau, president and CEO of Hawaiian Electric Industries, celebrating Hawaii's move to a 100-percent renewable future from NYSE, and David Scheinken, M.D., CEO of Agios Pharmaceuticals, at the Nasdaq.
On August 6, Intercept Pharmaceuticals’ (ICPT) stock price grew ~17.94% to $114.71—compared to the previous day’s closing price of $97.26. On August 6, Intercept Pharmaceuticals’ stock price closed at $114.71, which represents ~125% growth from its 52-week low of $51.05 on February 9.
Agios (AGIO) incurs narrower-than-expected loss in Q2. Additionally, higher license and collaboration/milestone fees lead to a significant year-over-year rise in revenues.
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 26.54% and 234.36%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Cambridge, Massachusetts-based company said it had a loss of $1.19 per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
–TIBSOVO ® Launch Underway Post FDA Approval for IDH1m R/R AML; Second Medicine Approved from Agios’ Discovery Platform in 12 Months–. –Entered License Agreement with CStone Pharmaceuticals to Develop ...
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Agios Pharmaceuticals, Inc. (NASDAQ: AGIO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 8:00 AM Eastern ...
Short interest is moderate for AGIO with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold AGIO had net inflows of $1.67 billion over the last one-month.
On Agios' (AGIO) second-quarter 2018 conference call, investor focus is likely to be on the launch preparations of the company's newly FDA approved leukemia drug, Tibsovo.
Short interest is moderate for AGIO with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold AGIO had net inflows of $719 million over the last one-month.
The biotech sector is in focus as bigwig Biogen gains on better-than-expected Q2 results. Others like Gilead, Amgen and Celgene too are slated to report shortly.
Agios (AGIO) gains an FDA approval for its lead pipeline candidate, Tibsovo, for the treatment of relapsed/refractory acute myeloid leukemia (AML) in patients with an IDH1 mutation.
CAMBRIDGE, Mass., July 23, 2018-- Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference ...
"This is a shift in the entire treatment paradigm," Agios CEO David Schenkein told the Business Journal. "This is obviously a very exciting day for Agios, but even more so, for patients who now have a treatment that wasn't previously available."
Agios Pharmaceuticals Inc said on Friday its oral drug to treat a type of leukemia was approved by the U.S. health regulator. The drug, Tibsovo, was approved on the basis of an early-stage trial to treat patients with acute myeloid leukemia - a cancer of the blood and bone marrow - whose disease has been resistant to treatment or has relapsed. There are about 20,000 new cases of acute myeloid leukemia in the United States each year, the company said.
CAMBRIDGE, Mass., July 20, 2018--- Approval of TIBSOVO ® was Based on Phase 1 Study Results, Including Rate and Duration of Complete Remission and CR with Partial Hematologic Recovery and Rate of Conversion ...
Five of the six analysts covering Athenex (ATNX) in July gave the stock a “buy” rating, and one analyst gave it a “hold” rating. The mean rating for Athenex stock is 2.17 with a target price of $28.33. In July, two of the ten analysts covering Agios Pharmaceuticals (AGIO) gave the stock a “strong buy” rating, six analysts gave it a “buy” rating, and two analysts gave Agios a “hold” rating.
NEW YORK, June 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Biglari ...
Agios (AGIO) and CStone Pharmaceticals sign an exclusive collaboration and license agreement for the development and commercialization of its lead pipeline candidate Tibsovo.
June 26 (Reuters) - Agios Pharmaceuticals Inc: * AGIOS AND CSTONE PHARMACEUTICALS ANNOUNCE EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE IVOSIDENIB IN GREATER CHINA * AGIOS ...
Discovered and developed by Agios, ivosidenib is an investigational, first-in-class, oral, targeted inhibitor of the mutant isocitrate dehydrogenase-1 (IDH1) enzyme. CStone Pharmaceuticals will be responsible for conducting the development and commercialization activities for ivosidenib in hematologic and solid tumor indications in the Territory, with an initial focus in acute myeloid leukemia (AML) and cholangiocarcinoma.